Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
$654.48
$9.02(1.24%)
At close: 4:00 PM EST
$654.48
$9.02(1.24%)
Day’s Range― - ―
52-Week Range$476.49 - $935.86
Previous CloseN/A
Volume208.99K
Average Volume (3M)1.08M
Market Cap
$69.37B
Enterprise Value$52.23B
Total Cash (Recent Filing)$7.47B
Total Debt (Recent Filing)$2.71B
Price to Earnings (P/E)15.7
Beta0.80
Next Earnings
Jan 30, 2026EPS Estimate
10.34Last Dividend Ex-Date
Aug 18, 2025Dividend Yield0.4%
Share Statistics
EPS (TTM)11.83
Shares Outstanding104,170,296
10 Day Avg. Volume858,952
30 Day Avg. Volume1,078,380
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)2.62
Price to Sales (P/S)5.41
P/FCF Ratio20.97
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda9.63
Forecast
1Y Price Target
$735.19Price Target Upside12.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Bulls Say, Bears Say
Bulls Say
EarningsRegeneron posted stronger-than-expected financial results for the third quarter, exceeding expectations on both revenue and earnings.
Financial ManagementThe company is on track to fully repay its development balance with Sanofi earlier than anticipated, indicating strong financial management.
Product PerformanceDupixent's continued outperformance, especially with new launches, supports increased revenue estimates for the coming years.
Bears Say
CompetitionEYLEA is expected to face continued pressure from biosimilars and competition, leading to a decrease in demand.
Manufacturing IssuesIssues at the Catalent manufacturing facility may delay the approval of EYLEA HD prefilled syringe, and Regeneron is seeking an alternative manufacturer.
R&D ExpensesRegeneron's 2026 R&D expenses are expected to increase significantly to support its expanding late-stage pipeline, indicating a potential rise in costs.
Regeneron News
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $476.49 and its highest was $935.86 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $69.37B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Jan 30, 2026 which is in 93 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Oct 28, 2025. The company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.655 by $2.175.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 0.4%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 10.34.
How many shares outstanding does Regeneron have?
Regeneron has 104,170,296 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $11.83 in its last earnings report, beating expectations of $9.655. Following the earnings report the stock price went up 11.818%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$735.19 (12.33% Upside)
$735.19 (12.33% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.99%
12-Months-Change
Fundamentals
Return on Equity
15.34%
Trailing 12-Months
Asset Growth
5.91%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
REGN Company Deck
REGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Regeneron demonstrated strong sales growth in key products like Dupixent and Libtayo, along with significant R&D pipeline progress. However, challenges such as affordability issues for EYLEA and FDA-related setbacks tempered some positive outcomes. Overall, the company shows a robust financial position and commitment to innovation, but faces operational hurdles that need addressing.View all REGN earnings summariesREGN Revenue Breakdown
53.72% Net product sales
42.65% Collaboration revenue
3.63% Other
REGN Stock 12 Month Forecast
Average Price Target
$735.19
▲(12.33% Upside)
Technical Analysis
Ownership Overview
0.26% Insiders
27.28% Mutual Funds
0.70% Other Institutional Investors
44.44% Public Companies and Individual Investors